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Enveloped  virus-like  particles  (VLPs)  are  increasingly  used  as  vaccines  and  immunotherapeutics.  Fre-
quently,  very  time  consuming  density  gradient  centrifugation  techniques  are  used for puriﬁcation  of
VLPs.  However,  the  progress  towards  optimized  large-scale  VLP  production  increased  the  demand  for
fast, cost  efﬁcient  and scale  able  puriﬁcation  processes.  We  developed  a chromatographic  procedure  for
puriﬁcation  of HIV-1  gag  VLPs  produced  in  CHO  cells.  The  clariﬁed  and  ﬁltered  cell  culture  supernatant  was
directly processed  on an anion-exchange  monolith.  The  majority  of host  cell  impurities  passed  through
the  column,  whereas  the  VLPs  were  eluted  by  a linear  or step  salt  gradient;  the  major  fraction  of  DNA  was
eluted prior to  VLPs  and  particles  in  the  range  of 100–200  nm  in  diameter  could  be separated  into  two
fractions.  The  earlier  eluted  fraction  was enriched  with  extracellular  particles  associated  to  exosomes  or
microvesicles,  whereas  the late  eluting  fractions  contained  the  majority  of  most  pure  HIV-1  gag  VLPs.
DNA  content  in  the  exosome-containing  fraction  could  not  be reduced  by  Benzonase  treatment  whichensity gradient centrifugation indicated  that the DNA  was  encapsulated.  Many  exosome  markers  were  identiﬁed  by proteomic  analysis
in  this  fraction.  We  present  a laboratory  method  that  could  serve  as  a basis  for rapid  downstream  pro-
cessing  of enveloped  VLPs.  Up  to  2000  doses,  each  containing  1  × 109 particles,  could  be processed  with
a  1  mL  monolith  within  47 min.  The  method  compared  to density  gradient  centrifugation  has  a  220-fold
improvement  in  productivity.
© 2016  The  Author(s).  Published  by Elsevier  B.V.  This  is an  open  access  article  under  the CC. Introduction
Enveloped virus-like particles (VLPs) are promising candidates
or vaccination, gene therapy, and cancer immunotherapy [1–7].
uriﬁcation of VLPs is in its infancy and used methods often have
een adopted from virus puriﬁcation procedures, mostly den-
ity gradient centrifugation and combinations of ﬁltration and
ow through chromatography [8–11]. It is often overlooked that
nveloped VLPs and viruses are secreted together with extracellular
esicles such as microvesicles and exosomes [12,13]. Such mixtures
re difﬁcult to separate and often the presence of microvesicles in
LP and virus preparations are ignored and their biological rel-
∗ Correspondence to: Muthgasse 18, 1190 Vienna, Austria.
E-mail address: alois.jungbauer@boku.ac.at (A. Jungbauer).
ttp://dx.doi.org/10.1016/j.chroma.2016.05.053
021-9673/© 2016 The Author(s). Published by Elsevier B.V. This is an open access articl
.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
evance is not understood [14,15]. Monoliths are well suited for
puriﬁcation of large bio-particles, such as plasmid DNA, viruses and
VLPs [16–22]. For plasmids, large scale processes have already been
established [23]. Pretreatment of the feedstock before puriﬁcation
by such methods as multiple depth and membrane ﬁltration steps
and polishing of viruses and VLPs often accounts for not only reduc-
tion in yield but also contributes to the costs of the process [8,24].
Thus, it is desirable to directly load the culture supernatant onto the
chromatography column with minimum efforts of pretreatment.
In this study we focus on HIV-1 gag VLPs as a model system.
These VLPs, using the structural protein gag of HIV-1, are produced
in CHO cells. Such an expression system secretes the VLPs into the
supernatant and high productivity can be obtained [25–28]. Thus
such a system would be suited for production of pandemic vac-
cines or requirements for treatment of large patient population [3].
e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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owever, the studied system must be strictly considered as a model
ystem.
The HIV-1 gag VLPs are composed of a lipid bilayer, which
riginate from the host cell, in our case the CHO cells. The gag
olyprotein drives the self-assembly of spherical particles, but-
ressing the lipid bilayer, and once assembled, bud from the cell
embrane [29]. The biophysical properties which are important for
uriﬁcation development are not exactly known. The physical size
s in the range of 100–150 nm in diameter [29], with density around
.18 g/cm3 [10]. It has been assumed that enveloped viruses have
ultiple positive and negative charges distributed on the surface
30]. This is the most important property to design an ion-exchange
hromatography step either in ﬂow through or binding and elut-
ng mode. The processes for such particles must be developed in an
mpirical manner, because their properties are not fully known.
A further complication of puriﬁcation of VLPs is the potential
ontamination of the feedstock with extracellular vesicles such as
icrovesicles and exosomes [12,13]. These particles usually range
rom 40 to 1000 nm in diameter although a lot of these particles
ave a size between 40 and 100 nm which is very close to enveloped
LPs [13]. The large vesicles are easily separated during the clariﬁ-
ation steps by centrifugation or ﬁltration while the vesicles of the
ame size as VLPs have to be separated during a chromatographic
uriﬁcation step based on the particles structure. Studies with HIV
iruses have shown that these vesicles carry similar membrane
roteins [15]. Budding processes for the virus and the extracellu-
ar vesicles are similar, or at least have been shown to be for HIV
12,15]. It is not clear to what extent CHO budding of VLPs and
xtracellular vesicles follow the same route. It is well know that
HO cells secrete such vesicles, because they have been considered
or use as a measure of the quality of the cell [31]. A mixture of
LPs or viruses and extracellular vehicles is extremely difﬁcult to
eparate [14]. In addition, the analysis and discrimination of VLPs
rom extracellular vesicles is very challenging since they are simi-
ar in size and are in a large part composed of the same structural
roteins. Usually, analytical methods for characterization of VLPs
re based on identiﬁcation of structural proteins and evaluation of
he particle number and particle size [32]. Evaluation of the parti-
le number and size can be done by nanoparticle tracking analysis
NTA). However, this method cannot distinguish between different
article structures and is associated with a variability of measure-
ents up to 15–20%, which is still in the acceptable error range
or accuracy of bioanalytical methods recommended by the FDA
33,34]. TEM is used as an orthogonal method for NTA, to corrob-
rate the particle size and as a visual proof for particle formation
ut does not provide any information about the particle compo-
ition. Biochemical methods such as Western blotting and mass
pectrometry (MS) are used for detection of structural proteins and
eptides and suggests information about the particle composition,
ut also detect unstructured protein impurities that are not assem-
led into particles. Impurities, such as dsDNA, frequently packaged
n extracellular vesicles [35] can be detected by ﬂuorescent nucleic
cid stains in combination with endonuclease treatment proce-
ures. Only the combination of multiple complementary analytical
ethods can gather conclusions about the particle structure [36].
VLP separation can be managed by a combination of ﬂow
hrough chromatography, membrane chromatography, micro-
ultraﬁltration steps, and size exclusion chromatography [8,37,38].
e have focused on monoliths with channels of 2 m in diameter.
n previous work, we were able to purify baculovirus by monoliths.
hese rod-shape infective viruses have a completely different phys-
cal shape compared to the enveloped VLPs. For VLPs, we assumed homogenous distribution of charged membrane proteins on the
urface whereas baculoviruses have a head region that accumulates
irus protein gp64 and is distinct from the tail [17].r. A 1455 (2016) 93–101
We  aimed to directly load the cell free culture supernatant
on a monolith column and the exclusive pretreatment, after cell
and cell debris removal by centrifugation, should consist only of
0.8 m membrane ﬁltration. Optional endonuclease pretreatment
was tested to reduce the dsDNA content before chromatogra-
phy. Binding and elution conditions must be found which allow
removal of host cell impurities and concentrate VLPs to a particle
number which would be equivalent to a vaccine. The pretreated
culture supernatant was loaded and respective gradients were
applied for elution. A combination of multiple complementary
methods (NTA, TEM, Western blotting) were applied to detect VLPs.
For discrimination between VLPs and other extracellular particles
proteomic analysis was performed and potentially encapsulated
dsDNA was detected after endonuclease treatment. We  also wanted
to benchmark our process with the most common method, density
ultracentrifugation.
2. Material and methods
2.1. Chemicals
All chemicals were purchased from Merck (Darmstadt,
Germany) or Sigma Aldrich (St. Louis, MO,  USA).
2.2. Expression of HIV-1 gag VLPs
For production of VLPs based on HIV-1 gag protein, a pQMCF
expression vector expressing HIV-1 gag protein under the control of
the CMV  promoter was constructed. For production CHOEBNALT85
cell line (Icosagen, Tartumaa, Estonia) grown at 37 ◦C was used.
Cells (6 × 106) were transfected by electroporation with 1 g of VLP
expression vector pQMCF-HIVgag. Forty eight h after transfection
700 g/mL of G418 Geneticin® (Gibco/Thermo Fischer, Waltham,
MA) was added to the selected plasmid-containing cell population.
After selection, on day 10, the temperature of the cell culture was
shifted to 30 ◦C and fed with CHO CD Efﬁcient FeedB (Thermo Fisher
Scientiﬁc, Waltham, MA USA) for 9 days. Cell culture media was a
mixture of CDCHO and 293SFM (Thermo Fisher Scientiﬁc, Waltham,
MA USA) including HT Supplement and Glutamax (Thermo Fisher
Scientiﬁc, Waltham, MA USA). Production of HIV-1 gag VLPs was
conﬁrmed by Western blot analysis detecting HIV-1 p24. After pro-
duction of the HIV-1 gag VLPs, cells were removed by centrifugation
(1000g, 30 min) and 0.01% NaN3, was  added.
2.3. Density gradient centrifugation
The HIV-1 gag VLPs were pelleted from the VLP containing cell
culture supernatant through a 20% (w/v) sucrose cushion at 77,100g
for 2.5 h at 4 ◦C by a Beckmann L8–80 M ultracentrifuge using a
SW41Ti rotor (Brea, CA, USA). The VLP-containing pellet was resus-
pended in PBS buffer and loaded onto a 20% – 60% (w/v) sucrose
gradient and centrifuged at 93,500g for 17.5 h at 4 ◦C. The gradient
was fractionated from the top in 300 L aliquots at 22 ◦C. Density
was determined gravimetrically (Sartorius, Göttingen, Germany)
and absorbance at 280 nm was  measured by NanoDropND-1000
(Thermo Fisher Scientiﬁc, Waltham, MA USA) at 22 ◦C.
2.4. Chromatographic experiments
2.4.1. Chromatographic equipment
Preliminary chromatographic experiments were conducted on
an Agilent Series 1100 System (Agilent, Waldbronn, Germany)
consisting of a well plate automatic liquid sampler (WP  ALS)
for injection, a degasser, a quaternary pump, and a diode array
detector (DAD). The ChemStation for LC 3D systems (Rev. B.
04.03) software was used for data acquisition and control. UV
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bsorbances were monitored at 280 and 260 nm simultaneously.
lution fractions were collected manually and pooled according to
he chromatograms.
Chromatographic experiments on preparative scale were per-
ormed on an ÄKTA explorer 100 equipped with a P-960
ample-pump and fraction collector (Frac-950) (GE Healthcare,
ppsala, Sweden). For control and data acquisition Unicorn soft-
are 10.1 was used. Conductivity, pH, and absorbance at 280 and
60 nm were monitored simultaneously. Elution fractions of 1 mL
ere collected by fraction collector and pooled according to the
hromatograms.
.4.2. Preliminary chromatographic experiments
Preliminary chromatographic experiments were performed on
n analytical scale using quaternary amine (QA), diethylamine
DEAE) and sulfate (SO3) CIMacTM analytical monoliths (V = 0.1 mL)
BIA Separations, Ajdovsˇcˇina, Slovenia). For anion-exchange chro-
atography, 20 mM Tris and 50 mM HEPES buffer systems were
ested over the pH range from 7.2 to 8.5 and for cation-exchange
hromatography 20 mM phosphate buffer was used over the pH
ange from 6.0 to 8.0. Optional 150 mM NaCl was added to
quilibration buffers (mobile phase A) for anion-exchange chro-
atography and all elution buffers (mobile phase B) contained 2 M
aCl. Analytical monoliths were equilibrated for 15 bed volumes
ith appropriate equilibration buffer. Aliquots (100 L to 500 L)
f HIV-1 gag VLP standard material obtained by density gradient
entrifugation or clariﬁed and 0.8 m ﬁltered (Millex AA ﬁlter, Mil-
ipore Bedford, MA,  USA) CHO supernatant were loaded onto the
onolith and eluted by a linear gradient 0–50% B in 50 bed volumes
ollowed by a regeneration step to 100% B for 30 bed volumes and
anitization with 1 M NaOH for 30 bed volumes. Flow rate during
hromatography was 1 mL/min.
.4.3. Preparative chromatographic puriﬁcation of HIV-1 gag
LPs
Preparative puriﬁcations of HIV-1 gag VLPs from clariﬁed and
.8 m ﬁltered (Millex AA ﬁlter, Millipore Bedford, MA,  USA) cul-
ure supernatant were conducted by anion-exchange with the 1 mL
adial ﬂow monoliths CIMmultus QA or CIMmultus DEAE (BIA Sep-
rations, Ajdovsˇcˇina, Slovenia). Equilibration buffer (mobile phase
) was 50 mM HEPES, 100 mM NaCl pH 7.2 for linear gradient elu-
ion and 50 mM HEPES, 350 mM NaCl pH 7.2 for stepwise elution.
 wash step of 20 bed volumes was introduced after loading and
efore linear gradient elution. For step gradient elution the wash
tep length was reduced to 15 bed volumes. Elution and regener-
tion was performed with 50 mM HEPES, 2 M NaCl pH 7.2 (mobile
hase B). Linear gradients were conducted from 0 to 50% B in 50 bed
olumes and stepwise elution was achieved by 0–25–45% B steps
ith a hold of 15 bed volumes each. After regeneration, sanitization
as performed with 1 M NaOH. Equilibration was  performed for 15
ed volumes, regeneration for 15 bed volumes and sanitization for
0 bed volumes. Flow rate during development of the puriﬁcation
rocess was 1 mL/min. After optimization of puriﬁcation procedure
he ﬂow rate was adjusted to 5 mL/min.
.5. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
SDS-PAGE) and Western blot analysis
NuPAGE Bis/Tris gels 4–12% (Invitrogen, Carlsbad, CA, USA) and
ES-SDS running conditions were used to perform electrophoresis
nder reducing conditions in accordance to manufacturer’s instruc-
ions. If required, samples were diluted in deionized water to obtain
imilar protein concentrations. SeeBlue® Plus2 Pre-stained Protein
tandard (Invitrogen, Carlsbad, CA, USA) was used as the protein
olecular weight ladder. Protein bands were stained by Coomassie
rilliant Blue G-250 based EZBlueTM Gel Staining Reagent (Sigmar. A 1455 (2016) 93–101 95
Aldrich, St. Louis, MO,  USA). After SDS-PAGE, proteins were elec-
troblotted onto a nitrocellulose membrane (Whatman, Dassel,
Germany). The membrane was blocked with 3% BSA in PBS-T (0.1%
w/v Tween-20 in PBS) for 2 h. Detection was performed by incu-
bation of primary mouse monoclonal antibody against HIV-1 p24
(Icosagen AS, Tartumaa, Estonia), diluted 1:1000 in PBS-T contain-
ing 1% BSA for 2 h, followed by secondary antibody incubation
with anti-mouse IgG conjugated with alkaline phosphatase (Sigma
Aldrich, St. Louis, MO,  USA), diluted 1:1000 in PBS-T with 1% BSA for
1 h. Visualization was  carried out by Lumi PhosTM (Thermo Fisher
Scientiﬁc, Waltham, MA  USA) on Lumi Imager (Boehringer Ingel-
heim, Ingelheim, Germany).
2.6. Protein concentration and dsDNA content
Protein concentration was determined by Bradford assay using
Coomassie blue G-250-based protein dye reagent (Bio-Rad Labora-
tories, Hercules, CA, USA). The calibration curve was obtained by
bovine serum albumin (BSA) standards diluted in TE-Buffer. DNA
content was  determined by Quant-iTTM PicoGreen® dsDNA kit (Life
technologies, Waltham, MA,  USA). Protein and DNA assays were
performed according to the particular manufacturer’s instructions
in 96-well plate format. Signals were measured by Genius Pro plate
reader (Tecan, Männedorf, Switzerland).
2.7. Nanoparticle tracking analysis (NTA)
For determination of particle concentration NTA measurements
were performed by a NanoSight LM-10 (Malvern Instruments Ltd.,
Worcestershire, UK) equipped with a blue laser (405 nm). Sam-
ples were serially diluted in particle-free water to reach a suitable
particle concentration (60–100 particles per video frame) for anal-
ysis. Videos (60 s) of three dilution steps for each sample were
captured at room temperature. The videos were analysed and eval-
uated by NTA 2.0 software. Camera level was  adjusted manually
and optimized analysis parameters were kept constant during all
measurements. Particle number was  evaluated for particles with
diameters between 100 and 200 nm.
2.8. Mass spectrometric analysis of proteins
Bands of interest were excised manually from Coomassie blue
stained 1D-gels. After washing and destaining [39] spots were
reduced with dithiothreitol and alkylated with iodoacetamide [40].
In-gel digestion was performed with trypsin (Trypsin Gold) with a
ﬁnal trypsin concentration of 20 ng/l in 50 mM aqueous ammo-
nium bicarbonate and 5 mM CaCl2. Digest proceeded for 8 h at 37 ◦C
[41]. Afterwards, peptides were extracted with three changes of
30 L of 5% TFA in 50% aqueous CH3CN supported by ultrasonica-
tion for 10 min  per change. Extracted peptides were dried down in
a vacuum concentrator (Eppendorf AG, Hamburg, Germany). De-
salted peptides were dissolved in 10 L 0.1% TFA and 1 L was
injected into the nano-HPLC Ultimate 3000 RSLC system (Thermo
Fisher Scientiﬁc, Waltham, MA,  USA). Sample pre-concentration
and desalting was  accomplished with a 5 mm Acclaim PepMap
-Precolumn (300 m inner diameter, 5 m particle size, and
100 Å pore size) (Thermo Fisher Scientiﬁc, Waltham, MA,  USA).
Separation was  performed on a 25 cm Acclaim PepMap C18 col-
umn  (75 m inner diameter, 3 m particle size, and 100 Å pore
size) with a ﬂow rate of 300 nl/min. The gradient started with
4% B (80% ACN with 0.1% formic acid) and increased to 35% B in
90 min. It was  followed by a washing step with 90% B. Mobile
Phase A consisted of mQ  H2O with 0.1% formic acid. For mass
spectrometric analysis a Triple TOF 6600 instrument (Sciex, Fram-
ingham, MA,  USA) was used. MS1  spectra were collected in the
range 400–1500 m/z. The 20 most intense precursors with charge
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tate 2–4 which exceeded 100 counts per second were selected
or fragmentation, and MS2  spectra were collected in the range
00–1800 m/z  for 150 ms.  The precursor ions were dynamically
xcluded from reselection for 10 s. The nano-HPLC system was  reg-
lated by Chromeleon 8.8 (Thermo Fisher Scientiﬁc, Waltham, MA,
SA) and the MS  by Analyst Software 1.7. Processed spectra were
earched via the software Protein Pilot (Sciex, Framingham, MA,
SA) in a UniProt database containing all proteins from Cricetu-
us griseus (identiﬁer: 10029) as well as all proteins from Human
mmunodeﬁciency virus 1 (identiﬁer: 11676) using the following
earch parameters: Global modiﬁcation: Cysteine alkylation with
odoacetamide, Species: Mus  musculus, Search effort: rapid, FDR
nalysis: Yes.
Proteins with more than 2 matching peptides at 95% conﬁdence
ere selected.
.9. Endonuclease treatment
Clariﬁed and ﬁltered cell culture supernatant was treated for 1 h
ith Benzonase purity grade II (Merck KgA, Darmstadt Germany) at
 ﬁnal concentration of 150 U/mL at 22 ◦C before 0.8 m ﬁltration
nd chromatographic puriﬁcation. For all analytical purposes, sam-
les were diluted in Benzonase buffer (1 M Tris-HCl, 30 mM MgCl2,
H 8.0) before being treated with Benzonase at a ﬁnal concentra-
ion of 150 U/mL at 37 ◦C for 1 h. For analytical purposes digestion
as stopped by addition of 50 mM EDTA.
.10. Transmission electron microscopy (TEM)
The samples were incubated for 1 min  on 400-mesh copper
rids, coated with Pioloform ﬁlm and shaded with carbon. After ﬁx-
tion with 2.5% glutaraldehyde solution for 15 min  and three wash
teps with water, samples were stained with 1% uranyl acetate solu-
ion for 30 s followed by air drying step [42]. The negatively stained
pecimens were analysed in a Tecnai G2 200 kV transmission elec-
ron microscope (FEI, Eindhoven, The Netherlands), operating at 80
eV.
. Results and discussion
VLPs were ﬁrst puriﬁed by density gradient ultracentrifugation
n order to produce a reference standard and to obtain mate-
ial for development of a chromatographic puriﬁcation method.
his experiment also served to allow comparison of the new pro-
ess with the well-established density gradient ultracentrifugation
ethod.
.1. Puriﬁcation of HIV-1 gag VLPs by density gradient
entrifugation
Two high speed ultracentrifugation steps were performed to
nrich HIV-1 gag VLPs at densities between 1.16 and 1.18 g/cm3
Fig. 1A) which are similar to values reported in literature for HIV-
 VLPs [10]. Density gradient fractions were analysed by Western
lot detecting HIV-1 gag speciﬁc p24, SDS-PAGE (Fig. 1B and C) and
he presence of VLP-like structures was conﬁrmed by TEM (Fig. 2
). Quantiﬁcation of particles was made by NTA and showed that
.6 × 1010 to 9.1 × 1010 part/mL were present in the pooled VLP
ractions, resulting in yields between 22.8–48.0%.
.2. Puriﬁcation processScreening experiments for development of a chromatographic
uriﬁcation process for HIV-1 gag VLPs were performed on an ana-
ytical scale. A strong (QA) and a weak (DEAE) anion-exchange as
ell as a strong cation-exchange (SO3) monoliths were tested inr. A 1455 (2016) 93–101
order to bind and elute HIV-1 gag VLPs. Puriﬁed standard material
or clariﬁed and ﬁltered cell culture supernatant containing HIV-1
gag VLPs were injected. Different buffer systems with pH ranges
from 6.0 to 8.5 were tested to elute HIV-1 gag VLPs by a linear gra-
dient from 0 to 1000 mM NaCl. HIV-1 gag VLPs did not bind to the
SO3 monolith, whereas QA and DEAE monoliths resulted in similar
performances and a 50 mM HEPES buffer system at pH 7.2 was iden-
tiﬁed to provide optimal conditions for elution of VLPs between 560
and 770 mM NaCl (45–90 mS/cm). The complex surface structure
of enveloped viruses and VLPs has not been well deﬁned. However,
a lot of enveloped viruses are negatively charged with isoelectric
points between 1.9 and 8.4 and viruses with very basic isoelectric
points have not been reported so far [30]. The phospholipid bilayer
originated from the host cell membrane during the VLP budding
processes and the associated membrane proteins contribute to the
binding. The polar head groups of the most common phospholipids
provide a negative net charge at physiological pH and are oriented
outside, towards the membrane surface [43]. Thus, it is reasonable
that the HIV-1 gag VLPs bind to anion-exchangers.
Puriﬁcation experiments were scaled up to 1 mL radial ﬂow
QA and DEAE monoliths and clariﬁed and ﬁltered cell culture
supernatant (50 mL)  was directly loaded onto the monoliths and
eluted by a linear gradient from 100 mM to 1000 mM NaCl at ﬂow
rates of 1 mL/min. A representative chromatogram obtained by QA
monolith is presented in Fig. 3A. Both monoliths were tested and
compared in terms of process recovery, yield, host cell (hc) protein,
and dsDNA depletion. Results obtained from the strong anion-
exchanger (Fig. 3, Table 1 and Table 2) and weak anion-exchanger
showed comparable purity (1.2 g total protein/109 particles and
15.0 ng dsDNA/109 particles puriﬁed by DEAE) and yield (20.8%
for DEAE). Further process development was done with the strong
anion-exchanger, because a higher operational stability can be
expected, because pH-shifts are smaller in strong ion-exchangers
[44]. Analysis of ﬂow through fraction (FT) by Western blot detect-
ing p24, (Fig. 3C) showed that nearly all HIV-1 gag VLPs bound to the
monolith which was conﬁrmed when measuring particle concen-
tration by NTA (Table 1) and by representative pictures generated
by TEM (data not shown). About 50% of hc proteins did not bind and
consequently were present in the ﬂow through fractions. VLPs were
eluted over a broad range of salt concentrations between 100 and
1000 mM (Fig. 3, Table 1) where about 15% of particles were eluted
at the beginning of the gradient at low salt concentrations with con-
ductivities between 12 and 32 mS/cm. Majority of dsDNA (65.6%)
was co-eluted with about one third of particles at an intermediate
salt concentration equivalent to 32–48 mS/cm but the majority of
particles (43.5%) were eluted at the end of the gradient between 48
and 89 mS/cm.
All three particle-containing fractions were examined by TEM
and the presence of particles was  conﬁrmed but no remarkable
visible differences between particles could be observed (Fig. 2).
However, different particle size distributions were measured by
NTA (Fig. 4), indicating that particles eluting in fraction P1 were
slightly smaller than particles eluted in P2 and P3. Particles elut-
ing in P3 were characterized by a broader particle size distribution
compared to particles eluted in P2. Additionally, a different protein
band pattern in SDS-PAGE (Fig. 3B) for these fractions was observed.
With focus on the main band at 55 kDa representing the gag protein
and a semi-quantitative evaluation of the band thickness, inter-
mediate and late eluting fractions P2 and P3 were more dominant
compared to P1. Furthermore, when the SDS-PAGE band proﬁle of
standard material obtained from density gradient centrifugation
(Fig. 1B) was compared to those of chromatographic eluting frac-
tions P1 to P3 (Fig. 3B) nearly no similarities were noted between
P1 and the standard material, but several analogous components
between P2, P3 and the standard material were identiﬁed. Particles
eluting in P1 were composed of a variety of contaminant proteins,
P. Steppert et al. / J. Chromatogr. A 1455 (2016) 93–101 97
Fig. 1. Absorbance and density proﬁle of sucrose gradient centrifugation of HIV-1 gag VLPs (A) and corresponding Coomassie stained SDS-PAGE (B) and Western blot analysis
(C).  5 L of each sample were loaded. Western blot detection was performed using a primary mouse monoclonal antibody against HIV-1 p24 (1:1000) and anti-mouse IgG
conjugated with alkaline phosphatase (1:1000) as secondary antibody. Visualization of bands was carried out by a chemiluminescent substrate detecting alkaline phosphatase.
Lane  numbers indicate fraction number in (A), M:  molecular mass marker.
Fig. 2. Transmission electron microscopy from HIV-1 gag VLPs puriﬁed by (A) sucrose density gradient centrifugation and anion-exchange chromatography eluted at low
(B)  intermediate (C) or high salt concentration (D). The scale bar corresponds to 500 nm in (A) and to 100 nm in (B) to (D).
Fig. 3. (A) Chromatogram of HIV-1 gag VLP puriﬁcation from 50 mL  0.8 m ﬁltered CHO cell culture supernatant applied to a 1 mL QA radial ﬂow monolith. Equilibration
buffer  was  50 mM HEPES, pH 7.2 and linear gradient elution was  performed from 100 to 1000 mM NaCl in 50 bed volumes at a ﬂowrate of 1 mL/min. (B) SDS-PAGE and (C)
Western blot analysis of collected fractions. The amount of loaded protein per lane was 785 ± 23 ng. Western blot detection was performed using a primary mouse monoclonal
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pntibody against HIV-1 p24 (1:1000) and anti-mouse IgG conjugated with alkaline
 chemiluminescent substrate detecting alkaline phosphatase. M:  molecular mass
hrough; W:  wash; P1-P3: fractions of eluting peaks; R: regenerate. Marked bands i
ut gag protein (band at 55 kDa in Fig. 3B) was not the main struc-
ural component or, conceivably, a great number of free hc proteins
ere also aggregated with these particles. Analysis of signiﬁcant
rotein bands (marked bands 1–15 in Fig. 3B) by MS  (results are
resented in the supplementary information) indicated that par-
icles eluting in P3 consisted mainly of hc membrane-associated
roteins (bands 12, 13 and 15 in Fig. 3B) and HIV-1 gag (band 14 in
ig. 3 B). The hc proteins were part of the VLPs and were incor-
orated into the particle during the budding process. Proteome
nalysis of particles eluting in P2 showed that a large number of
istones (bands 8–11 in Fig. 3 B) and an increased number of exo-
ome marker proteins (results are presented in the supplementary
nformation) were present in this fraction. Histones are usually
resent in the cell nucleus to package DNA and should not be incor-hatase (1:1000) as secondary antibody. Visualization of bands was carried out by
er, S: cell culture supernatant; L: load, ﬁltered cell culture supernatant; FT: ﬂow
were analysed by MS.
porated into correctly assembled VLPs. Therefore, we  assume that
we are eluting a portion of particles enriched with extracellular
vesicles which partially carry encapsulated DNA. DNA digestion by
Benzonase, done after the chromatographic method has been con-
verted to stepwise elution, showed that dsDNA content could be
minimized by enzymatic treatment in the VLP-containing fraction
to 0.9 ng dsDNA/109 particles but not in the fraction containing the
DNA (32.4 ng dsDNA/109 particles). This observation supports the
assumption that DNA must be encapsulated in these particles. It is
known that CHO cells produce a larger number of exosomes [31]
which bud simultaneously together with VLPs and carry encapsu-
lated DNA [35].
An endonuclease treatment step with 150 U/mL of Benzonase
for 1 h at room temperature was  introduced before chromatogra-
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Cig. 4. Particle size distribution measured by NTA. Fractions, corresponding to Fig. 3,
ere eluted form 1 mL  QA radial ﬂow monolith by a linear gradient from 100 to
000 mM NaCl in 50 bed volumes.
hy to optimize and improve DNA removal and to avoid potential
ompetitive binding of DNA on the AIEX surface. The dsDNA con-
ent of the cell culture supernatant was reduced 22.8 times (95.6%)
efore 0.8 m ﬁltration and loading onto the anion-exchange
onoliths. The elution proﬁle of endonuclease treated supernatant
hanged (compare Fig. 3 with Fig. 5). According to our expectations,
ignals of intermediate eluting fraction were reduced because the
ajority of DNA had been already digested into oligonucleotide
able 1
ass balance of HIV-1 gag VLP puriﬁcation with a 1 mL  radial ﬂow QA monolith by linear
reated CHO cell culture supernatant. (Buffer A: 50 mM HEPES, 100 mM NaCl, pH 7.2; Buf
Linear gradient elution
Volume (mL) Particles D 100–200 nm (part/mL) D
Load 50 5.7E + 10 10
FT  50 4.5E + 08 
Wash 20 2.9E + 08 
P1  11 3.9E + 10 1
P2  14 6.3E + 10 3
P3  20 6.E + 10 4
Recovery 9
Benzonase treatment before linear gradient elution
Volume (mL) Particles D 100–200 nm (part/mL) 
Load 50 9.5E + 10 
FT  50 3.0E + 07 
Wash 20 4.9E + 07 
P1  13 7.7E + 10 
P2  6 1.8E + 10 
P3  13 2.1E + 10 
P4  20 1.2E + 11 
Recovery 
d: not detectable.
able 2
omparison of puriﬁcation strategies and characterisation of puriﬁed HIV-1 gag VLPs.
Loading
volume (mL)
Flow rate
(mL/min)
Linear gradient elution 50 1 
Benzonase treatment before linear gradient elution 50 1 
Step  gradient elution (n=3) 50 1 
Step  gradient elution 160 1 
Step  gradient elution 160 5 
Density gradient centrifugation 10.2 – r. A 1455 (2016) 93–101
fragments before loading. Elution order of particles, particle yield
and particle concentration of elution fractions were not signiﬁ-
cantly affected by enzymatic treatment of starting material (Table 1,
Table 2). Changes are explained by different fraction sizes because
of differently pooled fractions and were within the methodical error
of measurement using NTA. The majority of HIV-1 gag VLPs (49.1%)
were eluted at high salt concentrations but residual dsDNA con-
tent of main HIV-1 gag VLP fraction was 3.2 times reduced (Table 1,
Table 2). The enzymatic pretreatment of the feedstock resulted in a
HIV-1 gag VLP fraction with an increased purity compared to puriﬁ-
cation of non-treated supernatant (Table 2). However, an additional
process step is required subsequently to remove the Benzonase.
Furthermore, it is commonly known that Benzonase is a huge cost
factor and usage of high concentrations during early process steps
might increase the total process costs. We  did not focus on the
optimization of the endonuclease treatment step and arrived at a
reasonable concentration of Benzoase for 1 h incubation time. This
short incubation time makes the process more robust and the whole
process sequence can be performed within one working day. Ben-
zonase seems expensive at ﬁrst glance, but also labour cost and
plant utilization are an important cost factor. When the process
time is reduced the plant can be more efﬁciently utilized. Only a
professional cost analysis using modelling tools such as BioSolve
(Biopharm Services, Chesham, UK) or SuperProDesigner (Intelligen
Inc., Scotch Plains, NJ, USA) could give information about the cost
effectiveness of the process operated with or without endonuclease
treatment.
Often stepwise elution facilitates puriﬁcation processes, espe-
cially for use on a large scale. The equilibration buffer was  adapted
 gradient elution. Loading material was 0.8 m ﬁltered and optional endonuclease
fer B: 50 mM HEPES, 2 M NaCl, pH 7.2; 0–50% B in 50 bed volumes).
istribution of particles % Total protein (g/mL) dsDNA (ng/mL)
0 448 12988
0.8 232 43
0.2 38 nd
5.1 229 46
0.7 241 30450
3.5 117 1281
0.3
% Total protein (g/mL) dsDNA (ng/mL)
100 379 717
0 190 46
0 45 nd
20.9 353 201
2.2 164 2136
5.8 59 1961
49.1 131 755
78.2
Yield (%) Total protein
/109 part.
(g/1 × 109
part.)
dsDNA
/109part.
(ng/1 × 109part.)
Productivity
(1 × 109part./mL/min)
43.5 1.9 21 8
49.1 1.1 6 11
41.9 ± 9.6 1.8 ± 0.3 11 ± 2 8
21.8 2.4 14 9
20.4 2.4 13 44
48.1 1.6 3 0
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Fig. 5. (A) Chromatogram of HIV-1 gag VLP puriﬁcation from 50 mL endonuclease treated and 0.8 m ﬁltered CHO cell culture supernatant by 1 mL QA radial ﬂow monolith.
Equilibration buffer was  50 mM HEPES, pH 7.2 and linear gradient elution was performed from 100 to 1000 mM NaCl in 50 bed volumes at a ﬂowrate of 1 mL/min. (B)
SDS-PAGE and (C) Western blot analysis of collected fractions. The amount of loaded protein per lane was 643 ± 33 ng. Western blot detection was performed using a primary
mouse  monoclonal antibody against HIV-1 p24 (1:1000) and anti-mouse IgG conjugated with alkaline phosphatase (1:1000) as secondary antibody. Visualization of bands
was  carried out by a chemiluminescent substrate detecting alkaline phosphatase. M:  molecular mass marker; S: cell culture supernatant; L1: endonuclease treated cell
culture  supernatant; L2: endonuclease treated and ﬁltered cell culture supernatant; P1-P4: fractions of eluting peaks; R: regenerate.
Fig. 6. (A) Chromatogram of HIV-1 gag VLP puriﬁcation eluted by a step gradient (0–25–45% B with a hold volume of 15 bed volumes) at a ﬂowrate of 1 mL/min. 50 mL
of  0.8 m ﬁltered CHO cell culture were loaded. Equilibration buffer was  50 mM HEPES, 350 mM NaCl, pH 7.2 and elution buffer 50 mM HEPES, 2 M NaCl, pH 7.2. (B) SDS-
PAGE  and (C) Western blot analysis of collected fractions. The amount of loaded protein per lane was 1234 ± 66 ng and 289 ng for the regenerate. Western blot detection
was  performed using a primary mouse monoclonal antibody against HIV-1 p24 (1:1000) and anti-mouse IgG conjugated with alkaline phosphatase (1:1000) as secondary
antibody. Visualization of bands was carried out by a chemiluminescent substrate detecting alkaline phosphatase. M:  molecular mass marker, S: cell culture supernatant; L:
load,  ﬁltered cell culture supernatant; FT: ﬂow through, W:  wash, P1-P2: fractions of eluting peaks, R: regenerate.
Table 3
Mass balance of HIV-1 gag VLP puriﬁcation with a 1 mL  radial ﬂow QA monolith step gradient elution. (Buffer A: 50 mM HEPES, 350 mM NaCl, pH 7.2; Buffer B: 50 mM HEPES,
2  M NaCl, pH 7.2; 0–25–45% B with a hold volume of 15 bed volumes).
Volume (mL) Particles D 100–200 nm (part/mL) Distribution of particles % Total protein (g/mL) dsDNA (ng/mL)
Load 50.0 10 100.0 349 10008
FT  50.0 2.3E + 07 0.1 171 40
Wash 15.0 9.2E + 09 7.5 371 65
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fP1  15.0 3.0E + 10 
P2  15.0 4.8E + 10 
Recovery 
o contain 350 mM NaCl, the length of the wash step was reduced
o 15 bed volumes, and elution was performed by 0–25–45% B
teps with a hold volume of 15 bed volumes each with elution
uffer containing 2 M NaCl. In Fig. 6, step elution proﬁle and corre-
ponding SDS-PAGE and Western blot results are shown and mass
alance is presented in Table 3. Robustness and reproducibility of
he puriﬁcation performance were demonstrated by three inde-
endent puriﬁcation cycles with two different supernatant batches.
he total process recovery of particles in all fractions were between
0.5 and >99.9%. Consistently, 50.3 ± 1.3% of hc proteins did not
ind to the monolith and were present in the ﬂow through frac-
ions and 33.6 ± 3.3% of hc proteins and about 14 ± 8.1% of particles
ould be removed during the wash step. Particles eluting during
he wash step, initially eluted in P1 during the linear gradient elu-
ion (compare Fig. 3B, P1 with Fig. 6B, W),  were either aggregated to
ree hc proteins or were not mainly assembled from the gag protein24.2 175 24652
38.8 98 602
70.5
(Fig. 6B, C). In peak one (P1, Fig. 6) generated by 25% B an average
of 80.8 ± 7.3% of dsDNA co-eluted with about one third of particles
(32.7 ± 9.4%) mainly consisting of extracellular vesicles. However,
co-elution of a noteworthy portion of correctly assembled HIV-1
gag VLPs cannot be excluded. Whereas, majority and most pure
HIV-1 gag VLPs eluted during the 45% B step resulting in a process
yield of 41.9 ± 9.6% (P2, Fig. 6 and Table 2). In summary, an aver-
age over-all hc protein depletion of 90.9% and an average dsDNA
depletion of 98.2% was  achieved.
3.3. Dynamic binding capacity (DBC)DBC was determined by direct loading of the ﬁltered culture
supernatant (Fig. 7). After about 100 mL  loading, the particles start
to breakthrough and after 200 mL  (equivalent to a total particle load
of 8.6 × 1012 part/mL QA) the breakthrough of particles reached
100 P. Steppert et al. / J. Chromatog
Fig. 7. (A) Dynamic binding capacity of ﬁltered CHO cell culture supernatant con-
taining HIV-1 gag VLPs. Flow through fractions (1–10) were measured by NTA to
monitor the VLP breakthrough and analysed by Picogreen assay to monitor dsDNA
breakthrough. (B) Western blot analysis of collected ﬂow through fractions (5 L of
fractions 1–10 in (A) were loaded). Western blot detection was performed using a
primary mouse monoclonal antibody against HIV-1 p24 (1:1000) and anti-mouse
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pgG conjugated with alkaline phosphatase (1:1000) as secondary antibody. Visu-
lization of bands was  carried out by a chemiluminescent substrate for detecting
lkaline phosphatase.
he starting concentration (4.3 × 1010 part/mL). This result could be
bserved by the increase of UV signals and was conﬁrmed by West-
rn blot analysis (Fig. 7B). The early breakthrough contained only
 minimal fraction of the total load (0.1%). Slightly shifted to the
reakthrough of HIV-1 gag VLPs, the breakthrough of dsDNA was
etected by Picogreen assay. To detect if there was  potential com-
etitive binding between the VLPs and DNA, which might reduce
he capacity for VLPs, the DBC was again determined by loading
ndonuclease pretreated and ﬁltered culture supernatant. A com-
arable binding capacity of 1.6 × 1012 part/mL QA was determined,
ndicating that there is no competitive binding of VLPs and DNA.
his result supports the application of the puriﬁcation process cope
ithout endonuclease pretreatment.
.4. Evaluation of the optimized puriﬁcation process
Using the optimized method that we deﬁned from DBC and elu-
ion conditions, we performed conﬁrmation runs where 160 mL
ltered culture supernatant (equivalent to a total particle number
f 1.0 × 1013 part/mL QA) was loaded at ﬂow rates of 1 mL/min and
 mL/min. In both cases yield was about 20% (Table 2) and the main
IV-1 gag VLP fraction contained a total number of 2.1 × 1012 and
.2 × 1012 particles, respectively. The residual dsDNA levels were
bout 20–40% above the limits required for a licensed vaccine (10 ng
sDNA/dose), when we assume that one vaccination dose consist
f 1.0 × 109 particles (Table 2). When a ﬂow rate of 5 mL/min was
pplied 2075 doses were puriﬁed within 47 min. In comparison the
rocess performed at 1 mL/min, yielded in 2219 doses within 4 hr. A 1455 (2016) 93–101
(Table 2). With slight improvements or for example by implementa-
tion of an endonuclease treatment after chromatography it would
be possible to reduce the DNA level to the values claimed by the
authorities.
4. Conclusion
Monoliths serve as a method to tackle extremely challenging
separation problems in the ﬁeld of bionanoparticles. Enveloped
VLPs are efﬁciently overproduced in CHO cells, but they are con-
taminated by hc proteins, hc DNA, and potentially by extracellular
particles. This method is able to separate these main impurities
including particles with different characteristic than HIV-1 gag
VLPs and is in principle suited for puriﬁcation of pandemic vac-
cines. The process at the current stage is a laboratory process but
all process parameters have been developed, which are needed to
scale up such a process. With a 1 mL  monolith, at least 160 mL
supernatant, equivalent to a total load of 1.0 × 1013 particles, were
processed within less than one hour. In comparison, a maximum of
20 mL  supernatant, equivalent to a total load of 9.3 × 1011 particles,
could be puriﬁed by the existing density gradient centrifugation
processes within 20 h resulting in about one-tenth of doses (230)
compared to monoliths. Currently 8 L monoliths are commercially
available and a 40 L monolith has been presented as an industrial
prototype. With an 8 L monolith, about 107 doses could be puriﬁed
and with the 40 L prototype about 5 × 107 doses. Our work provides
a direction for how a pandemic vaccine could be efﬁciently puriﬁed.
Acknowledgements
The research leading to these results has received funding from
the European Union Seventh Framework Programme (FP7/2007-
2013) under grant agreement no 312004. This work has been also
partly supported by the Federal Ministry of Science, Research and
Economy (BMWFW), the Federal Ministry of Trafﬁc, Innovation and
Technology (bmvit), the Styrian Business Promotion Agency SFG,
the Standortagentur Tirol and ZIT – Technology Agency of the City
of Vienna through the COMET-Funding Program managed by the
Austrian Research Promotion Agency FFG. We  thank Gerhard Sekot
for assisting with TEM pictures. P.A. was supported by the Austrian
Science Fund (project BioToP; FWF  W1224).
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.chroma.2016.05.
053.
References
[1] A.F. Rodrigues, H.R. Soares, M.R. Guerreiro, P.M. Alves, A.S. Coroadinha, Viral
vaccines and their manufacturing cell substrates: new trends and designs in
modern vaccinology, Biotechnol. J. 10 (2015) 1329–1344.
[2] R.S. Felberbaum, The baculovirus expression vector system: a commercial
manufacturing platform for viral vaccines and gene therapy vectors,
Biotechnol. J. 10 (2015) 702–714.
[3] F. Krammer, Emerging inﬂuenza viruses and the prospect of a universal
inﬂuenza virus vaccine, Biotechnol. J. 10 (2015) 690–701.
[4] F. Krammer, S. Nakowitsch, P. Messner, D. Palmberger, B. Ferko, R. Grabherr,
Swine-origin pandemic H1N1 inﬂuenza virus-like particles produced in insect
cells induce hemagglutination inhibiting antibodies in BALB/c mice,
Biotechnol. J. 5 (2010) 17–23.
[5] G.P. Pijlman, Enveloped virus-like particles as vaccines against pathogenic
arboviruses, Biotechnol. J. 10 (2015) 659–670.
[6] T. Frensing, Defective interfering viruses and their impact on vaccines and
viral vectors, Biotechnol. J. 10 (2015) 681–689.
[7] S.C. Lin, W.C. Liu, Y.F. Lin, Y.H. Huang, J.H. Liu, S.C. Wu,  Heterologous
prime-boost immunization regimens using adenovirus vector and virus-like
particles induce broadly neutralizing antibodies against H5N1 avian inﬂuenza
viruses, Biotechnol. J. 8 (2013) 1315–1322.
atog
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[42] M.A. Hayat, S.E. Miller, Negative Staining, McGraw-Hill, New York, 1990.
[43] L.K. Buehler, Cell membranes, in: Graland Science, Taylor and Francis Group,
2016.P. Steppert et al. / J. Chrom
[8] C.L. Efﬁo, J. Hubbuch, Next generation vaccines and vectors: designing
downstream processes for recombinant protein-based virus-like particles,
Biotechnol. J. 10 (2015) 715–727.
[9] P. Nestola, C. Peixoto, R.R.J.S. Silva, P.M. Alves, J.P.B. Mota, M.J.T. Carrondo,
Improved virus puriﬁcation processes for vaccines and gene therapy,
Biotechnol. Bioeng. 112 (2015) 843–857.
10] P.E. Cruz, C.C. Peixoto, K. Devos, J.L. Moreira, E. Saman, M.J.T. Carrondo,
Characterization and downstream processing of HIV-1 core and
virus-like-particles produced in serum free medium, Enzyme Microb.
Technol. 26 (2000) 61–70.
11] P. Pushko, P. Pumpens, E. Grens, Development of virus-like particle
technology from small highly symmetric to large complex virus-like particle
structures, Intervirology 56 (2013) 141–165.
12] S. Welsch, B. Müller, H.G. Kräusslich, More than one door—Budding of
enveloped viruses through cellular membranes, FEBS Lett. 581 (2007)
2089–2097.
13] G. Raposo, W.  Stoorvogel, Extracellular vesicles: exosomes, microvesicles, and
friends, J. Cell Biol. 200 (2013) 373–383.
14] J.W. Bess Jr., R.J. Gorelick, W.J. Bosche, L.E. Henderson, L.O. Arthur,
Microvesicles are a source of contaminating cellular proteins found in
puriﬁed HIV-1 preparations, Virology 230 (1997) 134–144.
15] M.  Hammarstedt, H. Garoff, Passive and active inclusion of host proteins in
human immunodeﬁciency virus type 1 Gag particles during budding at the
plasma membrane, J. Virol. 78 (2004) 5686–5697.
16] A. Podgornik, S. Yamamoto, M.  Peterka, N.L. Krajnc, Fast separation of large
biomolecules using short monolithic columns, J. Chromatogr. B 927 (2013)
80–89.
17] P. Gerster, E.M. Kopecky, N. Hammerschmidt, M.  Klausberger, F. Krammer, R.
Grabherr, C. Mersich, L. Urbas, P. Kramberger, T. Paril, M. Schreiner, K.
Nöbauer, E. Razzazi-Fazeli, A. Jungbauer, Puriﬁcation of infective
baculoviruses by monoliths, J. Chromatogr. A 1290 (2013) 36–45.
18] A. Jungbauer, R. Hahn, Polymethacrylate monoliths for preparative and
industrial separation of biomolecular assemblies, J. Chromatogr. A 1184
(2008) 62–79.
19] C. Tarmann, A. Jungbauer, Adsorption of plasmid DNA on anion exchange
chromatography media, J. Sep. Sci. 31 (2008) 2605–2618.
20] C.S. Burden, J. Jin, A. Podgornik, D.G. Bracewell, A monolith puriﬁcation
process for virus-like particles from yeast homogenate, J. Chromatogr. B 880
(2012) 82–89.
21] L. Urbas, B.L. Jarc, M.  Barut, M.  Zochowska, J. Chroboczek, B. Pihlar, E.
Szolajska, Puriﬁcation of recombinant adenovirus type 3 dodecahedric
virus-like particles for biomedical applications using short monolithic
columns, J. Chromatogr. A 1218 (2011) 2451–2459.
22] M.  Zaveckas, S. Snipaitis, H. Pesliakas, J. Nainys, A. Gedvilaite, Puriﬁcation of
recombinant virus-like particles of porcine circovirus type 2 capsid protein
using ion-exchange monolith chromatography, J. Chromatogr. B 991 (2015)
21–28.
23] J. Urthaler, R. Schlegl, A. Podgornik, A. Strancar, A. Jungbauer, R. Necina,
Application of monoliths for plasmid DNA puriﬁcation: development and
transfer to production, J. Chromatogr. A 1065 (2005) 93–106.
24] M.W.  Wolff, U. Reichl, Downstream processing of cell culture-derived virus
particles, Expert Rev. Vaccines 10 (2011) 1451–1475.
25] L. Cervera, S. Gutiérrez-Granados, M.  Martínez, J. Blanco, F. Gòdia, M.M.
Segura, Generation of HIV-1 Gag VLPs by transient transfection of HEK 293
suspension cell cultures using an optimized animal-derived component free
medium, J. Biotechnol. 166 (2013) 152–165.
[r. A 1455 (2016) 93–101 101
26] C.M. Thompson, E. Petiot, A. Mullick, M.G. Aucoin, O. Henry, A.A. Kamen,
Critical assessment of inﬂuenza VLP production in Sf9 and HEK293 expression
systems, BMC Biotechnol. 15 (2015).
27] W.  Akahata, Z.Y. Yang, H. Andersen, S. Sun, H.A. Holdaway, W.P. Kong, M.G.
Lewis, S. Higgs, M.G. Rossmann, S. Rao, G.J. Nabel, A virus-like particle vaccine
for  epidemic Chikungunya virus protects nonhuman primates against
infection, Nat. Med. 16 (2010) 334–338.
28] M.  Li, P.T. Schmitt, Z. Li, T.S. McCrory, B. He, A.P. Schmitt, Mumps  virus matrix,
fusion, and nucleocapsid proteins cooperate for efﬁcient production of
virus-like particles, J. Virol. 83 (2009) 7261–7272.
29] L. Deml, C. Speth, M.P. Dierich, H. Wolf, R. Wagner, Recombinant HIV-1 Pr55
gag  virus-like particles: potent stimulators of innate and acquired immune
responses, Mol. Immunol. 42 (2005) 259–277.
30] B. Michen, T. Graule, Isoelectric points of viruses, J. Appl. Microbiol. 109
(2010) 388–397.
31] A. Bedina Zavec, V. Kralj-Iglicˇ, M.  Brinc, T. Ficko Trcˇek, Microvesicles as a new
parameter for industrial bioprocess monitoring, Biotechnol. J. 10 (2015).
32] A. Zeltins, Construction and characterization of virus-like particles: a review,
Mol. Biotechnol. 53 (2013) 92–107.
33] U.S. Department of Health and Human Services Food and Drug Administration
Guidance for Industry, Bioanalytical Method Validation, in, Center for Drug
Evaluation and Research (CDER) Center for Veterinary Medicine (CVM), 2001.
34]  P. Kramberger, M.  Ciringer, A. Trancar, M.  Peterka, Evaluation of nanoparticle
tracking analysis for total virus particle determination, Virol. J. 9 (2012).
35] B.K. Thakur, H. Zhang, A. Becker, I. Matei, Y. Huang, B. Costa-Silva, Y. Zheng, A.
Hoshino, H. Brazier, J. Xiang, C. Williams, R. Rodriguez-Barrueco, J.M. Silva, W.
Zhang, S. Hearn, O. Elemento, N. Paknejad, K. Manova-Todorova, K. Welte, J.
Bromberg, H. Peinado, D. Lyden, Double-stranded DNA in exosomes: a novel
biomarker in cancer detection, Cell Res. 24 (2014) 766–769.
36] L.H. Lua, N.K. Connors, F. Sainsbury, Y.P. Chuan, N. Wibowo, A.P. Middelberg,
Bioengineering virus-like particles as vaccines, Biotechnol. Bioeng. 111 (2014)
425–440.
37] T. Vicente, A. Roldão, C. Peixoto, M.J.T. Carrondo, P.M. Alves, Large-scale
production and puriﬁcation of VLP-based vaccines, J. Invertebr. Pathol. 107
(2011) S42–S48 (Supplement).
38] T. Vicente, M.F.Q. Sousa, C. Peixoto, J.P.B. Mota, P.M. Alves, M.J.T. Carrondo,
Anion-exchange membrane chromatography for puriﬁcation of rotavirus-like
particles, J. Membr. Sci. 311 (2008) 270–283.
39] F. Gharahdaghi, C.R. Weinberg, D.A. Meagher, B.S. Imai, S.M. Mische, Mass
spectrometric identiﬁcation of proteins from silver-stained polyacrylamide
gel: a method for the removal of silver ions to enhance sensitivity,
Electrophoresis 20 (1999) 601–605.
40] C.R. Jiménez, L. Huang, Y. Qiu, A.L. Burlingame, In-gel digestion of proteins for
MALDI-MS ﬁngerprint mapping, in: Current Protocols in Protein Science, John
Wiley & Sons, Inc., 2001.
41] A. Shevchenko, M.  Wilm,  O. Vorm, M.  Mann, Mass spectrometric sequencing
of  proteins from silver-stained polyacrylamide gels, Anal. Chem. 68 (1996)
850–858.44] T.M. Pabst, G. Carta, pH transitions in cation exchange chromatographic
columns containing weak acid groups, J. Chromatogr. A 1142 (2007) 19–31.
